Marvel Biosciences Corp. to Present at the 22nd International Conference on Alzheimer's Drug Discovery
Calgary, Alberta--(Newsfile Corp. - September 17, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has been accepted to present at the start-up company forum at the 22nd International Conference of Alzheimer's Drug Discovery, a virtual conference on October 4 and 5th, 2021 hosted by the Alzheimer's Drug Discovery Foundation. The 2020 conference attracted close to...
2021-09-17 9:00 AM EDT
Marvel Biosciences Corp. Updates Market on Its Lead Caffeine Inspired Asset MB-204 for Neurological Diseases
Calgary, Alberta--(Newsfile Corp. - August 5, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to provide an update on its lead compound asset MB-204 ("MB-204") being developed for neurological conditions such as depression and anxiety, Alzheimer's and ADHD. Marvel's compound is a novel patented fluorinated derivative of the US-FDA approved Parkinson's disease drug Istradefylline...
2021-08-05 9:00 AM EDT
Marvel Biosciences Corp. Retains Virtus Advisory Group to Provide Corporate Communications Services
Calgary, Alberta--(Newsfile Corp. - August 3, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") is pleased to announce that it has retained Virtus Advisory Group Inc. ("Virtus") to develop and implement a strategic corporate communications program to increase the Company's exposure among industry stakeholders and investors across Canada. In connection with the engagement, Virtus has been awarded a consulting contract that includes a monthly fee of $7,000 and a grant of...
2021-08-03 4:30 PM EDT
Marvel Biosciences Corp. to Commence cGMP Manufacturing of Its Lead Asset MB-204
Calgary, Alberta--(Newsfile Corp. - July 21, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce that the Company's wholly owned subsidiary, Marvel Biotechnology Inc., has achieved a significant science milestone in the development of its lead compound MB-204. Marvel Biotechnology Inc. has entered into a current good manufacturing process (cGMP) manufacturing agreement (the "Agreement") with Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun") for the...
2021-07-21 8:30 AM EDT
Alphanco Venture Corp. Changes Name to Marvel Biosciences Corp. and Completes Acquisition of Marvel Biotechnology Inc.
Calgary, Alberta--(Newsfile Corp. - July 8, 2021) - Alphanco Venture Corp. (TSXV: AVC.P) (the "Company" or "AVC"), a capital pool company listed on the TSX Venture Exchange (the "TSXV"), is pleased to announce that it has closed its proposed "Qualifying Transaction," as defined under TSXV policies, being the acquisition of all of the outstanding shares (the "Transaction") of Marvel Biotechnology Inc., ("Marvel Biotech") effective June 14, 2021. In connection with closing of the Qualifying...
2021-07-08 1:24 PM EDT